EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2

Bobban Subhadra, Ragini Agrawal, Virender Kumar Pal, Agnes-Laurence Chenine, Jeffy George Mattathil iD, Amit Singh iD

Viruses · 2023

DOI: 10.3390/v15061299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Bobban Subhadra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biom Pharmaceutical Corporation, 2203 Industrial Blvd, Sarasota, FL 34234, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biom Pharmaceutical Corporatio.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far infected 762 million people with over 6.9 million deaths worldwide. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severities, are still an unmet global medical need. We studied Bi121, which is a standardized polyphenolic-rich compound isolated from Pelargonium sidoides, against recombinant vesicular stomatitis virus (rVSV)-pseudotyped SARS-CoV-2S (mutations in the spike protein) of six different variants of SARS-CoV-2. Bi121 was effective at neutralizing all six rVSV-ΔG-SARS-CoV-2S variants. The antiviral activity of Bi121 was also assessed against SARS-CoV-2 variants (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta), and Omicron) in Vero cells and HEK-ACE2 cell lines using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity against all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity. Bi121 fractions generated using HPLC showed antiviral activity in three fractions out of eight against SARS-CoV-2. The dominant compound identified in all three fractions using LC/MS/MS analysis was Neoilludin B. In silico structural modeling studies with Neoilludin B showed that it has a novel RNA-intercalating activity toward RNA viruses. In silico findings and the antiviral activity of this compound against several SARS-CoV-2 variants support further evaluation as a potential treatment of COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Chlorocebus aethiopsAnimalsHumansTandem Mass SpectrometryVero CellsAntiviral AgentsVesiculovirusSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

Bi121COVID-19Neoilludin BPelargonium sidoidesSARS-CoV-2antiviralintercalating agent

Substanzen

Antiviral AgentsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Biom Pharmaceutical Corporation, 2203 Industrial Blvd, Sarasota, FL 34234, USA.
  • Department of Microbiology and Cell Biology, Center for Infectious Disease Research, Indian Institute of Science (IISc), CV Raman Ave., Bengaluru 560012, India.
  • Integrated BioTherapeutics Inc., 4 Research Court, Suite 300, Rockville, MD 20850, USA.

ORCID-Profile: Jeffy George Mattathil, Amit Singh

Förderung

  • Biom Pharmaceutical Corporatio

Zitieren

APA

Subhadra, B., Agrawal, R., Pal, V. K., Chenine, A. L., Mattathil, J. G., & Singh, A. (2023). Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. Viruses. https://doi.org/10.3390/v15061299

Vancouver

Subhadra B, Agrawal R, Pal VK, Chenine AL, Mattathil JG, Singh A. Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. Viruses. 2023. doi:10.3390/v15061299

BibTeX
@article{Subhadra2023,
  author = {Subhadra, Bobban and Agrawal, Ragini and Pal, Virender Kumar and Chenine, Agnes-Laurence and Mattathil, Jeffy George and Singh, Amit},
  title = {Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15061299}
}
Kostenlos starten →